Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1741 to 1755 of 9026 results

  1. Savolitinib with osimertinib for treating EGFR-mutated MET-overexpressed or amplified advanced non-small-cell lung cancer after osimertinib [ID6494]

    Awaiting development Reference number: GID-TA11626 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Omental lymph node transfer for lymphoedema of the limbs

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  3. Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435]

    Awaiting development Reference number: GID-TA11535 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Serplulimab with chemotherapy for neoadjuvant and adjuvant treatment of untreated gastric cancer [ID6760]

    Awaiting development Reference number: GID-TA11975 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Sepiapterin for treating hyperphenylalaninaemia in phenylketonuria in people of any age [ID6750]

    Awaiting development Reference number: GID-TA11982 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Zasocitinib for treating moderate to severe plaque psoriasis [ID6700]

    Awaiting development Reference number: GID-TA11926 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Dorocubicel for treating haematological cancer when a suitable donor is unavailable for an allogeneic haematopoietic stem cell transplant [ID6521]

    Awaiting development Reference number: GID-TA11673 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Domestic Abuse

    In development Reference number: GID-NG10449 Expected publication date:  08 October 2027

    NICE guideline
    In development

  9. Shared decision-making: practical guidance for health and social care professionals

    Awaiting development Reference number: GID-QS10097 Expected publication date: TBC

    Quality standard
    Awaiting development

  10. Safeguarding adults in care homes

    Awaiting development Reference number: GID-QS10147 Expected publication date: TBC

    Quality standard
    Awaiting development

  11. Supporting independent living and preventing isolation in adults of working age with social care needs

    Awaiting development Reference number: GID-QS10149 Expected publication date: TBC

    Quality standard
    Awaiting development

  12. Pembrolizumab for treating advanced or recurrent endometrial cancer with mismatch repair deficiency [ID6710]

    Awaiting development Reference number: GID-TA11931 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Luspatercept for treating anaemia caused by myelodysplastic syndromes (including review of TA844) [ID6696]

    Awaiting development Reference number: GID-TA11914 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Miniature lens system implantation for advanced age-related macular degeneration

    Awaiting development Reference number: GID-HTG10468 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  15. Xanomeline tartrate–trospium chloride for treating schizophrenia [ID6716]

    Awaiting development Reference number: GID-TA11925 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development